AI Summary
We reviewed 33 live results for abrilada (adalimumab afzb) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilars and Prescription Medication.
Comparison Table
Recommended
Abrilada (adalimumab-afzb)
Source: Pfizer (Malaysia) Sdn. Bhd.
Description
Abrilada is a prescription biopharmaceutical and a biosimilar to Humira (adalimumab). It functions as a TNF blocker used to treat chronic inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. It is typically available as a 40 mg/0.8 mL solution for injection in a single-dose pre-filled pen, featuring a citrate-free formulation for subcutaneous administration.
Best for
rheumatoid arthritis management, chronic inflammatory conditions, patients seeking biosimilar alternatives, subcutaneous injection therapy and ankylosing spondylitis treatment
View Details
Rating
ABRILADA (adalimumab-afzb)
Source: Pfizer Inc.
Description
ABRILADA (adalimumab-afzb) is a biologic medication and tumor necrosis factor (TNF) blocker designed to treat various inflammatory conditions. As an FDA-approved interchangeable biosimilar to Humira®, it can be substituted at the pharmacy level. This citrate-free medication is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is available in several forms including a single-dose prefilled pen (ABRILADA Pen), single-dose prefilled syringe, and institutional use vial in various strengths.
Best for
rheumatoid arthritis patients, humira biosimilar alternatives, adults with plaque psoriasis, citrate-free injection preference and crohn's disease management
View Details
Rating
Abrilada
Source: Pfizer Private Limited
Description
Abrilada is an HSA-approved adalimumab biosimilar available in Singapore. It is offered in 20mg/0.4ml and 40mg/0.8ml single-dose pre-filled syringes and 40mg/0.8ml pre-filled pens. It provides an alternative for patients requiring TNF blocker therapy for inflammatory diseases.
Best for
biologic therapy, chronic inflammation management and subcutaneous injection
View Details
Rating
| Compare | Abrilada (adalimumab-afzb) | ABRILADA (adalimumab-afzb) | Abrilada |
|---|---|---|---|
| Source | Pfizer (Malaysia) Sdn. Bhd. | Pfizer Inc. | Pfizer Private Limited |
| Description | Abrilada is a prescription biopharmaceutical and a biosimilar to Humira (adalimumab). It functions as a TNF blocker used to treat chronic inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. It is typically available as a 40 mg/0.8 mL solution for injection in a single-dose pre-filled pen, featuring a citrate-free formulation for subcutaneous administration. | ABRILADA (adalimumab-afzb) is a biologic medication and tumor necrosis factor (TNF) blocker designed to treat various inflammatory conditions. As an FDA-approved interchangeable biosimilar to Humira®, it can be substituted at the pharmacy level. This citrate-free medication is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is available in several forms including a single-dose prefilled pen (ABRILADA Pen), single-dose prefilled syringe, and institutional use vial in various strengths. | Abrilada is an HSA-approved adalimumab biosimilar available in Singapore. It is offered in 20mg/0.4ml and 40mg/0.8ml single-dose pre-filled syringes and 40mg/0.8ml pre-filled pens. It provides an alternative for patients requiring TNF blocker therapy for inflammatory diseases. |
| Best for | rheumatoid arthritis management, chronic inflammatory conditions, patients seeking biosimilar alternatives, subcutaneous injection therapy and ankylosing spondylitis treatment | rheumatoid arthritis patients, humira biosimilar alternatives, adults with plaque psoriasis, citrate-free injection preference and crohn's disease management | biologic therapy, chronic inflammation management and subcutaneous injection |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Abrilada (adalimumab-afzb) from Pfizer (Malaysia) Sdn. Bhd.."
I picked this because Abrilada is a registered biosimilar in Malaysia and an FDA-designated interchangeable product, providing a clinically effective and cost-efficient alternative for patients managing inflammatory diseases.
Share this search
Related Finds